Listed

Relmada Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2016

Filed with the SEC on May 9, 2016 and accepted by EDGAR at May 9, 2016, 17:13 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2016-01-01 to 2016-03-31$609.1kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2015-07-01 to 2016-03-31$5.6mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2016-01-01 to 2016-03-31−$2.7mus-gaap:OperatingIncomeLoss
Operating income9 months2015-07-01 to 2016-03-31−$13.1mus-gaap:OperatingIncomeLoss
Net income3 months2016-01-01 to 2016-03-31−$1.9mus-gaap:NetIncomeLoss
Net income9 months2015-07-01 to 2016-03-31$342.7kus-gaap:NetIncomeLoss
Diluted EPS3 months2016-01-01 to 2016-03-31−$0.15us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2015-07-01 to 2016-03-31$0.03us-gaap:EarningsPerShareDiluted
Basic EPS3 months2016-01-01 to 2016-03-31−$0.15us-gaap:EarningsPerShareBasic
Basic EPS9 months2015-07-01 to 2016-03-31$0.03us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2016-01-01 to 2016-03-3112,003,789 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2015-07-01 to 2016-03-3112,137,518 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2015-07-01 to 2016-03-31−$10.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2015-07-01 to 2016-03-31$539.2kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2016-03-31$11.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-03-31$11.8mus-gaap:AssetsCurrent
Total assetsAt period end2016-03-31$12.7mus-gaap:Assets
Current liabilitiesAt period end2016-03-31$2.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-03-31$2.5mus-gaap:Liabilities
Shareholders' equityAt period end2016-03-31$10.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-16-013088. Last ingested by Listed: Nov 13, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.